Mass balance approaches for estimating the intestinal absorption and metabolism of peptides and analogues: theoretical development and applications.
A theoretical analysis for estimating the extent of intestinal peptide and peptide analogue absorption was developed on the basis of a mass balance approach that incorporates convection, permeability, and reaction. The macroscopic mass balance analysis (MMBA) was extended to include chemical and enzymatic degradation. A microscopic mass balance analysis, a numerical approach, was also developed and the results compared to the MMBA. The mass balance equations for the fraction of a drug absorbed and reacted in the tube were derived from the general steady state mass balance in a tube: [formula: see text] where M is mass, z is the length of the tube, R is the tube radius, Pw is the intestinal wall permeability, kr is the reaction rate constant, C is the concentration of drug in the volume element over which the mass balance is taken, VL is the volume of the tube, and vz is the axial velocity of drug. The theory was first applied to the oral absorption of two tripeptide analogues, cefaclor (CCL) and cefatrizine (CZN), which degrade and dimerize in the intestine. Simulations using the mass balance equations, the experimental absorption parameters, and the literature stability rate constants yielded a mean estimated extent of CCL (250-mg dose) and CZN (1000-mg dose) absorption of 89 and 51%, respectively, which was similar to the mean extent of absorption reported in humans (90 and 50%). It was proposed previously that 15% of the CCL dose spontaneously degraded systematically; however, our simulations suggest that significant CCL degradation occurs (8 to 17%) presystemically in the intestinal lumen.(ABSTRACT TRUNCATED AT 250 WORDS)
Sinko
P J
PJ
College of Pharmacy, Rutgers University, Piscataway, New Jersey 08855-0789.
Leesman
G D
GD
Amidon
G L
GL
D002433:Cefaclor / Q000493:pharmacokinetics; D002436:Cefatrizine / Q000493:pharmacokinetics; D006801:Humans; D007328:Insulin / Q000493:pharmacokinetics; D007408:Intestinal Absorption; D008954:Models, Biological; D010455:Peptides / Q000737:chemistry / Q000493:pharmacokinetics*; D010539:Permeability
D007328:Insulin; D010455:Peptides; D002433:Cefaclor; D002436:Cefatrizine